Clinical trial
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
NCT03532295 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
- Lead sponsor
- Washington University School of Medicine
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 20, 2020
- Completion date
- October 31, 2025
- Enrollment
- 51 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.